The FDA has approved Journavx, a new non-opioid painkiller designed to treat moderate to severe acute pain. Unlike opioids, ...

Share and Cite: Hinz, B. and Kenyon, J. (2025) Getting to a Diagnosis: A Rare Case of TFE3 Translocation Renal Cell Carcinoma ...

There is also contrast therapy that is vividly used in physiotherapy, especially sports physiotherapy, where a cold bath is ...

Though long COVID, or post-acute sequelae of SARS-CoV-2 (PASC), is more common in adults than in kids, 1.3% of US children ...

For the first time in 20 years, the Food and Drug Administration has approved a new pharmaceutical approach to treating pain.

Ubrelvy and Nurtec are prescription medications taken to treat migraines. Though they share similarities, Ubrelvy is for acute treatment, while Nurtec can be taken for immediate symptom relief.

The US Food and Drug Administration (FDA) has approved a non-opioid drug for severe post-surgical pain, which could “redefine ...

Journavx, a new non-opioid pain medication, offers a safer alternative for managing acute pain while reducing the risk of ...

CenExel, a leading network of clinical research sites, proudly congratulates and announces its role in supporting Vertex Pharmaceuticals’ clinical studies that led to the FDA approval of JOURNAVX™ ...

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Symbravo (meloxicam and ...

Dr. Sanjay Gupta said Tuesday that the approval of a new non-opioid pain medication is “a pretty big deal.” “This is a pretty ...